Relmada Therapeutics's three largest insider shareholders as of May 14, 2026 are Sergio Traversa (Chief Executive Officer, 1.30Mn shares), Maged Shenouda (Chief Financial Officer, 800.00K shares), Paul Edward Kelly (Chief Operating Officer, 502.30K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Sergio Traversa | Chief Executive Officer | 1,300,000 | 0 | 16 Dec, 2025 |
| Maged Shenouda | Chief Financial Officer | 800,000 | 0 | 16 Dec, 2025 |
| Paul Edward Kelly | Chief Operating Officer | 502,295 | 0 | 06 Nov, 2025 |
| Chuck Ence | Cao And Coo | 403,931 | 0 | 06 Nov, 2025 |
| Cedric O'Gorman | Chief Medical Officer | 10,121 | 0 | 24 May, 2023 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 12 Dec, 2025 | Charles J Casamento | Stock Appreciation Rights | A | 164,000 | $0.00 | 164,000 | D | A |
| 12 Dec, 2025 | Paul Edward Kelly | Stock Appreciation Rights | A | 828,000 | $0.00 | 828,000 | D | A |
| 12 Dec, 2025 | Chuck Ence | Stock Appreciation Rights | A | 828,000 | $0.00 | 828,000 | D | A |
| 15 Dec, 2025 | Sergio Traversa | Common Stock | A | 27,500 | $4.12 | 1,300,000 | D | P |
| 15 Dec, 2025 | Maged Shenouda | Common Stock | A | 11,665 | $4.12 | 800,000 | D | P |
| 12 Dec, 2025 | Fabiana Fedeli | Stock Appreciation Rights | A | 164,000 | $0.00 | 164,000 | D | A |
| 12 Dec, 2025 | John Glasspool | Stock Appreciation Rights | A | 164,000 | $0.00 | 164,000 | D | A |
| 12 Dec, 2025 | Maged Shenouda | Stock Appreciation Rights | A | 828,000 | $0.00 | 828,000 | D | A |
| 12 Dec, 2025 | Sergio Traversa | Stock Appreciation Rights | A | 1,198,000 | $0.00 | 1,198,000 | D | A |
| 05 Nov, 2025 | Paul Edward Kelly | Common Stock | A | 90,000 | $2.20 | 502,295 | D | P |
| 05 Nov, 2025 | Sergio Traversa | Common Stock | A | 272,500 | $2.20 | 1,272,500 | D | P |
| 05 Nov, 2025 | Chuck Ence | Common Stock | A | 136,000 | $2.20 | 403,931 | D | P |
| 05 Nov, 2025 | Maged Shenouda | Common Stock | A | 500,000 | $2.20 | 788,335 | D | P |
| 26 Aug, 2025 | Sergio Traversa | Common Stock | A | 80,545 | $0.62 | 814,569 | D | P |
| 27 Aug, 2025 | Sergio Traversa | Common Stock | A | 129,455 | $0.67 | 944,024 | D | P |
| 28 Aug, 2025 | Sergio Traversa | Common Stock | A | 55,976 | $0.74 | 1,000,000 | D | P |
| 26 Jun, 2025 | Fabiana Fedeli | Stock Option (right to buy) | A | 100,000 | $0.00 | 100,000 | D | A |
| 26 Jun, 2025 | John Glasspool | Stock Option (right to buy) | A | 100,000 | $0.00 | 100,000 | D | A |
| 26 Jun, 2025 | Paul Edward Kelly | Stock Option (right to buy) | A | 400,000 | $0.00 | 400,000 | D | A |
| 26 Jun, 2025 | Charles J Casamento | Stock Option (right to buy) | A | 100,000 | $0.00 | 100,000 | D | A |